Carbapenem-Based Antibiotics Market in North America report 2028 | Size, Share, Growth by Business Market Insights

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. North America Carbapenem-Based Antibiotics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. North America Carbapenem-Based Antibiotics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1
5.1.2 Rising prevalence of bacterial infections
5.1.3 Increased demand for last-resort antibiotics
5.1.4 Growth in hospital-acquired infections

5.2 Market Opportunities

5.2.1
5.2.2 Development of novel carbapenem derivatives
5.2.3 Demand in emerging markets healthcare
5.2.4 Expansion in injectable antibiotic formats

5.3 Future Trends

5.3.1
5.3.2 Focus on antibiotic stewardship programs
5.3.3 Increased research on resistant pathogens
5.3.4 Development of combination therapies

5.4 Impact of Drivers and Restraints

6. North America Carbapenem-Based Antibiotics Market Regional Analysis

6.1 North America Carbapenem-Based Antibiotics Market Overview

6.2 North America Carbapenem-Based Antibiotics Market Revenue 2019-2028 (US$ Million)

6.3 North America Carbapenem-Based Antibiotics Market Forecast Analysis

7. North America Carbapenem-Based Antibiotics Market Analysis – by Type

7.1 Meropenem

7.1.1 Overview
7.1.2 Meropenem: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Doripenem

7.2.1 Overview
7.2.2 Doripenem: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Imipenem

7.3.1 Overview
7.3.2 Imipenem: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Tebipenem

7.4.1 Overview
7.4.2 Tebipenem: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Carbapenem-Based Antibiotics Market Analysis – by Indication

8.1 Bacterial Meningitis

8.1.1 Overview
8.1.2 Bacterial Meningitis: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

8.2 Acute Pelvic Infections

8.2.1 Overview
8.2.2 Acute Pelvic Infections: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

8.3 Respiratory Tract Infections

8.3.1 Overview
8.3.2 Respiratory Tract Infections: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Intra-Abdominal Infections

8.4.1 Overview
8.4.2 Intra-Abdominal Infections: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Urinary Tract Infections

8.5.1 Overview
8.5.2 Urinary Tract Infections: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Carbapenem-Based Antibiotics Market Analysis – by Distribution Channel

9.1 Retail Pharmacies

9.1.1 Overview
9.1.2 Urinary Tract Infections: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

9.2 Online Pharmacies

9.2.1 Overview
9.2.2 Urinary Tract Infections: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

9.3 Hospital Pharmacies

9.3.1 Overview
9.3.2 Urinary Tract Infections: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Carbapenem-Based Antibiotics Market – North America Analysis

10.1 North America

10.1.1 North America Carbapenem-Based Antibiotics Market Breakdown, by Key Country, 2022 and 2028 (%)
10.1.1.1 North America Carbapenem-Based Antibiotics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 US: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.1.1 US: North America Carbapenem-Based Antibiotics Market Breakdown, by Type
10.1.1.1.2 US: North America Carbapenem-Based Antibiotics Market Breakdown, by Indication
10.1.1.1.3 US: North America Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel

10.1.1.2 Canada: North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.2.1 Canada: North America Carbapenem-Based Antibiotics Market Breakdown, by Type
10.1.1.2.2 Canada: North America Carbapenem-Based Antibiotics Market Breakdown, by Indication
10.1.1.2.3 Canada: North America Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel

10.1.1.3 Mexico : North America Carbapenem-Based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)

10.1.1.3.1 Mexico : North America Carbapenem-Based Antibiotics Market Breakdown, by Type
10.1.1.3.2 Mexico : North America Carbapenem-Based Antibiotics Market Breakdown, by Indication
10.1.1.3.3 Mexico : North America Carbapenem-Based Antibiotics Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. North America Carbapenem-Based Antibiotics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 ACS Dobfar S.p.A

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Iterum Therapeutics plc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 DAEWOONG PHARMACEUTICAL CO., LTD

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Aurobindo Pharma Ltd

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Gland Pharma Limited

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Merck & Co., Inc.

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Sumitomo Dainippon Pharma Co., Ltd.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Savior Lifetec

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Pfizer Inc.

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Spero Therapeutics

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights